CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 120 target
Drug / intervention
Graminex WSPE +2 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06889753
NCT06889753Phase 2RecruitingOn TrackUpdated 7mo ago

A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Effect of Pollen Extracts on Menopausal Symptoms in Healthy Women.

Graminex LLC·interventional·Posted Mar 21, 2025·Updated Nov 19, 2025

In Brief

A Phase 2 clinical trial evaluating Graminex WSPE, Graminex LSPE, and 1 other intervention for Menopausal Women. Currently recruiting, targeting 120 participants across 1 site.

Detailed Summary

The goal of this study is to investigate the effect of pollen extracts on menopausal symptoms in healthy women The main question it aims to answer is: What is the difference in change in severity of menopausal symptoms as assessed by the total Menopause Rating Scale (MRS) score from baseline at Week 36 between Graminex Water Soluble Pollen Extract (WSPE), Lipid Soluble Pollen Extract (LSPE), and Placebo? Participants will be asked to complete the MRS assessment tool to rate their menopausal symptoms while receiving either WSPE, LSPE, or Placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
CollaboratorsKGK Science Inc.

Timeline

Phase 2Recruiting
2026
First PostedMar 21, 2025
Enrollment StartOct 29, 2025
Primary CompletionAug 1, 2026
TodayJul 1, 2026
Enrollment to primary: 9 monthsPosted 1.3 years agoPrimary completion in 1 month

Interventions

Graminex WSPEdietary

Graminex Water Soluble Pollen Extract is standardized to 6% amino acids.

Graminex LSPEdietary

Graminex Lipid Soluble Pollen Extract is standardized to 7% phytosterols.

Placebodietary

Placebo